ALK and non-small cell lung carcinoma: A study revealed that pembrolizumab monotherapy has shown significant improvements in overall survival as a first-line treatment compared with conventional chemotherapy for locally advanced or metastatic non-small-cell lung cancer without sensitising EGFR or ALK alterations when PDL1 TPS ≥ 1% [7].